1986
DOI: 10.1097/00004850-198604000-00001
|View full text |Cite
|
Sign up to set email alerts
|

Amitriptyline Pharmacokinetics and Clinical Response: 1. Free and Total Plasma Amitriptyline and Nortriptyline

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
10
0

Year Published

1987
1987
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(12 citation statements)
references
References 0 publications
2
10
0
Order By: Relevance
“…Optimally, [I] is taken as the hepatic inlet concentration (Miners et al, 2010b), but given the unavailability of key pharmacokinetic parameters (particularly absorption rate constant) for amitriptyline, doxepin, and mianserin, the maximum drug plasma concentration (C max ) was used as the estimate of [I] in the calculation of the AUC ratio. Amitriptyline (50 mg dose): mean C max 0.15 mM (Kukes et al, 2009), fraction unbound in plasma (fu) 0.065 (Baumann et al, 1986). Assuming linear kinetics, the C max expected for a single 150 mg dose of amitriptyline is 0.45 mM.…”
Section: Methodsmentioning
confidence: 99%
“…Optimally, [I] is taken as the hepatic inlet concentration (Miners et al, 2010b), but given the unavailability of key pharmacokinetic parameters (particularly absorption rate constant) for amitriptyline, doxepin, and mianserin, the maximum drug plasma concentration (C max ) was used as the estimate of [I] in the calculation of the AUC ratio. Amitriptyline (50 mg dose): mean C max 0.15 mM (Kukes et al, 2009), fraction unbound in plasma (fu) 0.065 (Baumann et al, 1986). Assuming linear kinetics, the C max expected for a single 150 mg dose of amitriptyline is 0.45 mM.…”
Section: Methodsmentioning
confidence: 99%
“…A detailed list of the values and equations used for the sensitivity analysis for hepatic extraction, absorption, liposome–drug binding, and liposome elimination is presented in Table S5 (Supporting Information). Finally, the sensitivity of the model to K eff was examined by varying B : P 57, 90 and f u 95–97 within clinically feasible ranges and computing K pu and K eff with the modified values. To be consistent, the modified values of B : P and f u were also utilized to compute K 1 and K 3 .…”
Section: Methodsmentioning
confidence: 99%
“…Data supporting the existence of an SLTER for At are less robust. Several studies were able to demonstrate either a linear [4,17,18,26,28,34,55,56] or curvilinear relationship [5,7,22,35,36,53], but many studies did not find any relationship between serum levels and therapeutic effect [2,10,11,12,24,25,27,33,39,46]. These results are based on the sum of the serum levels (C At+Nt ) of At (C At ) and its demethylated metabolite Nt (C Nt ).…”
Section: Introductionmentioning
confidence: 99%